计算溶液所需的质量、体积或浓度。
,适用于对基线干扰要求严格的色谱和分析工作流程。
避光,-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Allisartan isoproxil (ALS-3) is an orally potent, selective, non-peptide inhibitor of Angiotensin II Type 1 . Allisartan isoproxil is also an antihypertensive agent. Allisartan isoproxil may inhibit angiotensin-aldosterone system and oxidative stress. Allisartan isoproxil lowers blood pressure and protects the organs, preventing cerebrovascular damage. Allisartan isoproxil (80-320 mg/kg/d) has shown toxicity in rat models by targeting liver organs
In Vivo
The metabolic pathway of Allisartan isoproxil is relatively simple, and Allisartan isoproxil is completely and directly converted to EXP-3174 by esterase during gastrointestinal absorption . Allisartan isoproxil\t(20, 80 and 320 mg/kg/day; po; for 26 weeks) decreases body weight at 80-320 mg/kg/day dose, in Sprague-Dawley rats . Allisartan isoproxil\t(30 mg/kg/day; po in diet; for 55 weeks) significantly decreases stroke-related death and prolongs lifespan in stroke-prone renovascular hypertensive rats (RHR-SP). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Femal and male Sprague-Dawley rats Dosage: 20, 80 and 320 mg/kg Administration: Result: Decreased body-weight gain at 320 mg/kg/day in both sexes as well as at the 80-mg/kg/day dose in females. Decreased erythrocyte parameters in males, and decreased heart weight and exacerbation of chronic progressive nephropathy (CPN) severity in males at 80 and 320 mg/kg/day.
Form:Solid
IC50& Target:Angiotensin II Type 1